Lonza Shares Jump on U.S. Manufacturing Facility Buy From Roche
By Helena Smolak
Lonza shares rose after the Swiss life-sciences company agreed to acquire a manufacturing facility in the U.S. from Roche for around $1.2 billion in cash as it seeks to boost growth of its biologics division.
At 0809 GMT, shares of Lonza were up 4.4% at CHF503.40. If maintained until close, Lonza shares would trade the highest year to date.
Lonza said Wednesday that it would raise its mid-term target for 2024-28 as the deal is expected to increase sales growth.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
March 20, 2024 04:45 ET (08:45 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing